Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE)

Seoul National University

Status: Unknown

Conditions: Coronary Artery Disease; Percutaneous Coronary Intervention; Acute Coronary Syndrome; Angina Pectoris

Treatments: Device: Alpine

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02845804

HOST-ALPINE

Details and patient eligibility

About

The objectives of this study are

1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent
2. To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition™/Alpine™ stent
3. To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition™/Alpine ™ stent and other contemporary drug-eluting stents which had established their own registry

Full description

Secondary endpoints of this study are

Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI

Target vessl failure

Composite rate of cardiac death and any MI, 3 years

Composite rate of all death and any MI

Composite rate of all death, any MI, and any repeat revascularization

Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy

Enrollment: 1,533 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient agrees to participate in this study by signing the informed consent form.

Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form

Exclusion criteria

• There are no exclusion criteria for this registry.

Trial design

1,533 participants in 1 patient group

Alpine

Description:

The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™

Treatment:

Device: Alpine